{"entity": "publication", "iuid": "631b388e809144529cabd94871030e83", "timestamp": "2026-08-22T08:32:11.539Z", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/631b388e809144529cabd94871030e83.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/631b388e809144529cabd94871030e83"}}, "title": "Neither Gastric Bypass Surgery Nor Diet-Induced Weight-Loss Affect OATP1B1 Activity as Measured by Rosuvastatin Oral Clearance.", "authors": [{"family": "Hovd", "given": "Markus", "initials": "M", "orcid": "0000-0002-6077-0934", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/40bec1eda0684e43a25fb3a9552d9f03.json"}}, {"family": "Robertsen", "given": "Ida", "initials": "I"}, {"family": "Johnson", "given": "Line Kristin", "initials": "LK"}, {"family": "Krogstad", "given": "Veronica", "initials": "V"}, {"family": "Wegler", "given": "Christine", "initials": "C"}, {"family": "Kvitne", "given": "Kine Eide", "initials": "KE"}, {"family": "Kringen", "given": "Marianne Kristiansen", "initials": "MK"}, {"family": "Skovlund", "given": "Eva", "initials": "E"}, {"family": "Karlsson", "given": "Cecilia", "initials": "C"}, {"family": "Andersson", "given": "Shalini", "initials": "S"}, {"family": "Artursson", "given": "Per", "initials": "P"}, {"family": "Sandbu", "given": "Rune", "initials": "R"}, {"family": "Hjelmes\u00e6th", "given": "J\u00f8ran", "initials": "J"}, {"family": "\u00c5sberg", "given": "Anders", "initials": "A"}, {"family": "Jansson-L\u00f6fmark", "given": "Rasmus", "initials": "R"}, {"family": "Christensen", "given": "Hege", "initials": "H"}], "type": "journal article", "published": "2023-05-00", "journal": {"title": "Clin Pharmacokinet", "issn": "1179-1926", "volume": "62", "issue": "5", "pages": "725-735", "issn-l": null}, "abstract": "Rosuvastatin pharmacokinetics is mainly dependent on the activity of hepatic uptake transporter OATP1B1. In this study, we aimed to investigate and disentangle the effect of Roux-en-Y gastric bypass (RYGB) and weight loss on oral clearance (CL/F) of rosuvastatin as a measure of OATP1B1-activity.\n\nPatients with severe obesity preparing for RYGB (n = 40) or diet-induced weight loss (n = 40) were included and followed for 2 years, with four 24-hour pharmacokinetic investigations. Both groups underwent a 3-week low-energy diet (LED; < 1200 kcal/day), followed by RYGB or a 6-week very-low-energy diet (VLED; < 800 kcal/day).\n\nA total of 80 patients were included in the RYGB group (40 patients) and diet-group (40 patients). The weight loss was similar between the groups following LED and RYGB. The LED induced a similar (mean [95% CI]) decrease in CL/F in both intervention groups (RYGB: 16% [0, 31], diet: 23% [8, 38]), but neither induced VLED resulted in any further changes in CL/F. At Year 2, CL/F had increased by 21% from baseline in the RYGB group, while it was unaltered in the diet group. Patients expressing the reduced function SLCO1B1 variants (c.521TC/CC) showed similar changes in CL/F over time compared with patients expressing the wild-type variant.\n\nNeither body weight, weight loss nor RYGB per se seem to affect OATP1B1 activity to a clinically relevant degree. Overall, the observed changes in rosuvastatin pharmacokinetics were minor, and unlikely to be of clinical relevance.", "doi": "10.1007/s40262-023-01235-5", "pmid": "36988826", "labels": [], "xrefs": [{"db": "pmc", "key": "PMC10181972"}, {"db": "pii", "key": "10.1007/s40262-023-01235-5"}], "notes": [], "created": "2026-08-21T11:09:34.290Z", "modified": "2026-08-21T11:09:34.373Z"}